U.S. Medicare limits coverage for Biogen’s Alzheimer’s drug -Breaking
[ad_1]
© Reuters. FILEPHOTO: Aduhelm (Biogen’s controversially-approved drug for the early stages of Alzheimer’s disease) is seen at Butler Hospital in Providence. U.S., June 16th, 2021. Jessica Rinaldi/Pool via REUTERS(Reuters) – The final policy of coverage for Biogen Inc (NASDAQ) was issued by the U.S. government’s health insurance plan. It stated that Aduhelm would only be covered for patients participating in clinical trials.
The Centers for Medicare and Medicaid Services stated that coverage would be granted for drugs like Aduhelm if it is approved by the Food and Drug Administration.
[ad_2]